The specter of generic challenges has long loomed around copyright’s blockbuster drug, Viagra, sparking questions about the future of related pharmaceutical ventures. While early years saw significant gains, the patent expiration has created the path for less expensive substitutes, possibly lowering revenue and presenting a genuine danger for sta